(GHD) [6] .
In our recent study, we found that by western ligand blot analysis, there is no overlap between prepubertal control subjects and patients with complete GHD (cGHD), whereas there is some overlap between these groups during puberty [11] .
Recently, using IGFBP-3 RIA, Blum and Ranke reported more than 95% sensitivity and specificity for diagnosis of GHD [12] . However, Martha et al. and Phillip et al. reported that there was a definite overlap between short children without any hormonal problems and patients with GHD [13, 14] .
In this study, we measured serum IGFBP-3 levels by RIA in sera from normal children, from normal short children (NS) and from patients with GHD to clarify the utility of IGF13P-3 level as a diagnostic marker for GHD.
Methods and Subjects
Method 1) Anti-human IGFBP-3 antisera and purified human IGFBP-3 for iodination were obtained from Dr. W.F. Blum. IGFBP-3 was iodinated and purified by one of us (M.S.), as modified from the method of Blum. A serum standard calibrated to purified IGFBP-3 was used to prepare a standard curve. Five microliters of serum standard, control or unknown were diluted (1: 456) with assay buffer before analysis using a dilutor (Compulator, Wheaton Instruments). Serum levels demonstrated parallelism with purified human as well as recombinant human IGFBP-3. The antisera did not cross react with IGF-I, IGF-II, IGFBP-1 or IGFBP-2.
The sensitivity of the assay was 0.3ng/ml and half-maximal displacement occurred at 5ng/ml. After correction for dilution this corresponds to 0.14 and 2.3mg/L respectively. The intraassay variation ranged from 8-10% at 1mg/L to 0.9%-4% at 3-4mg/L.
The interassay variation was 16% at 1mg/L, 11% at 2mg/L, 6.2% at 4.5 mg/L and 8.6% at 7.5mg/L. Measurements were performed in duplicate and in batches of 80 samples by 3 different technicians. To insure the greatest accuracy, samples with initial levels less than 1mg/L were repeated at a dilution of 1: 121. sensitivity: 84% (<10 years), 64% (>10 years). When cGHD and pGHD are analyzed separately, the sensitivity for GHD is as follows: cGHD: 100% (<10 years) and 88% (>10 years); pGHD: 58% (<10 years) and 33% (>10 years).
5) Among the patients with GHD older than 15
years old, 22 patients were evaluated for secondary hypogonadism. Of these patients, only 1 of 12 with untreated secondary hypogonadism (7 Table 2 . Sensitivity and specificity of IGFBP-3 NS, normal short children. Percentage of patients with NS and GHD (cGHD and pGHD) whose IGFBP-3 levels were above and below the cutoff level at each age and sex. The results are shown separately depending on whether the patients are below or above the age of ten.
cGHD and 5 pGHD) had an IGFBP-3 level above the cutoff level. In contrast, out of 10 pubertal patients without secondary hypogonadism (3 cGHD and 7 pGHD), 9 patients showed IGFBP-3 levels above the cutoff level at each age. There is a significant difference between the ratios (P<0.005) for GHD patients with hypogonadism and those without hypogonadism.
The IGFBP-3 levels of these GHD patients together with normal levels for each Tanner stage are shown in Fig. 4 . 
Discussion
The specificity for diagnosis of GHD was about 90%, which is similar to the results obtained by Blum et al. [12] . The sensitivity for diagnosis of cGHD was more than 90%. Therefore the usefulness of IGFBP-3 measurement for screening GHD was proved.
As shown in Table 2 , IGFBP-3 measurement for the diagnosis of pGHD is not so useful as cGHD. The sensitivity for pGHD was much lower than that reported by Blum et al., although they did not classify GHD into two types as we did into cGHD and pGHD. One reason for the difference in the usefulness of IGFBP-3 in cGHD and pGHD is easy to understand: the severity of deficiency is greater in cGHD than in pGHD, by definition.
Another possibility is the limitation of GH stimulation tests such as poor reproducibility [15, 16] and false positive ratios. We reported that the false positive ratio of arginine and insulin tests in short children was 22-23% [17] . The difference in the sensitivity between younger (<10 years) and older (>10 years) GHD patients may reflect the higher ratio of pGHD to cGHD in the older group. However, two other possibilities may explain the lower sensitivity for GHD after the age of ten: (1) some patients with a constitutional delay in growth and adolescence (CDGA) who had transient GHD [18, 19] were included, although we think this type of transient GHD is not a spectrum of GHD in a true sense but a physiological event.
(2) IGFBP-3 levels increase during puberty, independent of the GH-IGF-I axis.
Speculation (1) is likely to be true because we did not perform so-called testosterone or estrogen priming with GH stimulation tests in necessary cases. In our personal experience (not published), these CDGA patients with transient GHD are usually partial GHD by our definition. Thus, speculation (1) partially explains the fact that the sensitivity of IGFBP-3 testing for pGHD after the age of 10 is lower than that for pGHD before that age. However, we cannot explain the limitation of IGFBP-3 measurement after the age of ten solely by speculation (1), since two patients who were thought to have pGHD and cGHD before GH therapy was started at prepubertal age and who showed IGFBP-3 levels above the cutoff levels at pubertal age, were ascertained to have pGHD and cGHD when GH therapy was discontinued after puberty had developed almost fully.
Speculation (2) is supported by the following fact about GHD patients with or without secondary hypogonadism. Among the twenty-two pa-tients with GHD evaluated for secondary hypogonadism, the ratio of patients with GHD whose IGFBP-3 levels were above the age-matched cutoff level for GHD was significantly lower in the patients with GHD associated with secondary hypogonadism than in those without secondary hypogonadism.
A similar difference in IGFBP-3 levels between GHD with hypogonadism and that without hypogonadism using the Tanner-matched normal values, as shown in Fig. 4 , also supports the speculation (2). This speculation is also consistent with our previous report where we showed an overlap in IGFBP-3 levels on western ligand blot between pubertal control and untreated pubertal or sex-hormone treated (but not treated with GH)
pubertal patients with GHD [11] . Furthermore, this speculation is analogous to partial dependence of the serum IGF-1 concentration upon gonadal steroids (independent of GH) as reported by Attie and Grumbach [20] .
